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Abstract 
 
The aim of this study was to describe the many ways in which quality of life 
(QoL) measurement may potentially be advantageous in routine clinical 
dermatology practice. Thirteen members of the EADV Task Force on Quality of 
Life, eight dermatologists, three health psychologists, one epidemiologist and 
one pharmacoepidemiologist, independently listed all of the ways they thought 
this may be advantageous. 108 different way of using QoL information in clinical 
practice were suggested (median per participant=8, range=4-15), and were 
classified into 20 descriptive groups. These were sorted into five categories: 
Inform clinical decisions, Clinician-patient communication, Awareness of skin 
disease burden, Informing the consultation and Clinical service administration.  
The wide range of potential benefits identified may encourage clinicians to use 
these measures but also highlights many areas requiring evidence to establish 
the true value of routine use of QoL measures. 
 
 
Introduction 
 
The aim of this paper is to identify in what ways health-related quality of life 
(QoL) measurement may be of benefit in routine dermatology clinical practice.  
Since the first dermatology disease specific QoL measure publication1 30 years 
ago, the assessment of patientsǯ QoL is now frequently included in dermatology 
research studies2.  The measurement of QoL using validated instruments is 
recommended in dermatology therapy guidelines in many countries3,4,5 and 
consequently many clinicians worldwide have become familiar with these 
measures.  Anecdotally, some clinicians also use them in their routine clinical 
work but there is little published about such usage and a systematic review 
found limited evidence of impact6.   Some advantages and disadvantages of 
routine use of QoL measures in dermatology clinics7,8,9,10 and other 
specialties11,12,13 have since been described. 
 
The European Academy of Dermatology and Venereology (EADV) Task Force on 
QoL considers that there are several ways in which the measurement of QoL in 
clinical practice may benefit patients, support cliniciansǯ decision taking and 
contribute to delivery of high standards of care, though the evidence for this is 
very limited.  The aim of this Opinion Statement is to describe the many ways in 
which the use of QoL measures may be advantageous in clinical practice.  This 
Opinion Statement also aims to encourage clinicians to use QoL measures in 
practice and to be a source of reference.  An additional aim is to identify aspects 
of the use of QoL measures in clinical practice for which more research is needed 
to establish their actual, evidence based, value. 
 
 
Methods 
 
The Opinion Statement is confined to QoL measures, and does not address other 
components of Patient-Reported Outcomes (PROs), such as those recording 
symptoms, patient satisfaction or preference. 
 
All members of the EADV Task Force on QoL, including dermatologists, 
psychologists and other health care professionals, were invited to contribute. A 
draft protocol was reviewed by all those who expressed interest in the study and 
changes were made.  Each participant was asked to independently write a list of 
all the ways in which they considered QoL measurement is or could be useful in 
dermatology clinical practice.  This was carried out before reviewing the 
literature, in order to encourage original thinking among participants and to 
capture what is actually practiced.  All participants were asked to identify 
published articles of relevance that they were aware of in order to support this 
Opinion Statement. 
 
All responses were examined independently by AYF and SS: each item was 
identified and classified.  Consensus over classification was then reached during 
three detailed data definition meetings between AYF and SS. 
 
 
Results 
 
All 36 members of the EADV Task Force on QoL were invited to contribute, 13 of 
these (36%) took part. Eight dermatologists, three health psychologists, one 
epidemiologist and one pharmacoepidemiologist, from 11 European countries, 
participated: six (46%) were female.   
 
A total of 108 items were submitted by the 13 participants (median per 
participant= 8, range 4-15).  These were grouped under 20 descriptive headings 
(Table 1) and assigned to five categories: Inform clinical decision, Clinician-
patient communication, Impact on clinician and patient, Informing the 
consultation and Clinical service administration. 
 
A summary of the key points identified by participants, with illustrative 
participant quotations (Appendix 1), is given under five main categories and 20 
descriptive headings as follows: 
 
1. Inform clinical decisions 
 
Aid treatment decision taking 
 
Quality of life information may improve clinical decisions by making them more 
patient-centred.  Quality of life scores can inform decisions relating to choosing 
appropriate therapy strategies, whether to discharge or admit.  For example the 
Rule of Tens, that includes a QoL score, can be used to inform decisions over 
psoriasis therapy. (Quote 1) 
 
Guideline use 
 
Clinicians in many countries already use QoL measures routinely as 
recommended by national guidelines, to inform decisions especially relating to 
therapy of severe psoriasis. (Quote 2) 
 
Shared decision taking 
 
The use of QoL measures may encourage patientsǯ involvement in shared 
decision-making. Patientsǯ knowledge of non-medical aspects of their disease is complementary to the clinicianǯs expertise in medical factors. (Quote 3) 
 
Treatment goals 
 
For many patients, particularly for those with chronic skin conditions, as well as 
for the clinician, improvement in QoL is the main treatment goal.  Quality of life 
scores may guide therapy decisions, based on common treatment goals. They 
also inform the clinician when considering what potential risk will be tolerated 
by the patient. (Quote 4) 
 
Treatment adjustment at follow-up 
 
Quality of life scores can aid clinical decision-making such as dose adjustment or 
follow up therapy change, e.g. to reduce identified QoL impact more quickly. 
Treatment effects can be monitored over several follow-ups using QoL scores. 
(Quote 5) 
 
Discharge decisions 
 
QoL scores can influence the clinician to take more appropriate discharge 
decisions, for example if scores are high, delaying discharge or arranging 
additional support after discharge. (Quote 6) 
 
2. Clinician-patient communication 
 
Clinician-patient relationship 
 Systematic assessment of patientsǯ QoL in outpatients may enhance the clinician-
patient relationship, especially if results are discussed during consultation. Their 
use demonstrates to the patient the clinicianǯs awareness of the QoL impact 
experienced by the patient and indicates that the clinician cares about the 
patient and their preferred outcomes, not just the disease. (Quote 7) 
 
Clinician-patient enhanced dialogue 
 
Reviewing the patientǯs responses to the QoL questionnaire items may provide 
structure to and direct the clinical discussion to areas of patient concern, 
encouraging an overlapping understanding of the disease between clinician and 
patient.  Use of QoL measures may facilitate further discussion about treatment 
satisfaction, disease burden and treatment preferences. (Quote 8) 
 
3. Awareness of skin diseases burden 
 
Impact on clinician 
 
Use of QoL measures can make clinicians more aware of the patientǯs 
perspective, the burden experienced by the patient and their family14 and that  
lesion severity is not necessarily correlated with impact on QoL.  Clinicians may 
become more aware of the likely course of the impact of the condition on the 
patient and that clinically ǲcuredǳ conditions may still impact QoL . At a glace the 
domains that are most affected are identified, so the discussion can be more 
focussed. Issues such as shame or depression may be revealed and clinicians may 
be more likely to counsel the patient and consider referral for psychological help. 
(Quote 9) 
 
Impact on patient 
 Use of QoL measures may help verbalise a patientǯs feelings and give the patient 
greater insight and awareness of their disease and a sense of greater control 
over their disease and the consultation. It allows the patient to express their 
problems in a wider context than a traditional symptom based framework. One 
participant asserted that the use of QoL measures in itself may improve 
treatment outcome.  Score changes over time help patients to be aware of 
changes in their disease impact and might make them more interested in their 
treatment outcome, leading to improved adherence. (Quote  10) 
 
4. Informing the consultation: information aid for prognosis, monitoring, 
screening, adherence and referral 
 
Structured clinical assessment 
 
Structured assessment of QoL should be a part of the overall assessment of 
disease severity, helping to limit observer variation. 
 
Prediction outcomes/prognosis 
 
An understanding of the current QoL burden on a patient may inform a 
clinicianǯs predictions concerning patient therapy adherence, commitment to 
long term therapy and likely therapeutic outcome. (Quote 11) 
 
Adherence/compliance 
 
If by the use of QoL measures a patient is aware that their clinician understands 
their QoL burden, this may improve patient satisfaction and 
adherence/compliance with treatment. (Quote 12) 
 
Screening 
 Use of QoL measures can act as a screening process to reveal ǲhiddenǳ physical,  
psychological and adjustment problems, to identify patients who may need 
referral to other specialists and to identify patients who may need additional 
support or care. (Quotes 13) 
 
Monitoring of disease course 
 
Regular use of QoL measures can be used to assist monitoring the course of a 
condition or the effectiveness of therapy. Score change can be informative and 
alert the physician to the need for consideration of therapy change. 
Improvement in QoL may be the most important outcome of their care for many 
patients as well as for many clinicians. (Quotes 14) 
 
Education 
 
Use of QoL measures, by revealing specific problems, may allow individualisation 
of educational input to the patient.  Their use may also assist in the education of 
health care professionals, for example medical and nursing students, to help 
them understand the wider burden of skin disease. (Quote 15) 
 
Referral to other services 
 Systematic assessment of patientsǯ QoL, by revealing specific individual 
problems, may inform decisions concerning appropriate referral to other 
specialists or support services. (Quote 16) 
 
5. Clinical service administration 
 
Guideline use/development 
 
The importance of understanding the QoL impact of skin disease on patients is 
recognized in many national guidelines, such as for severe psoriasis15, where 
QoL scores are part of the recommended criteria for therapy decisions.  (Quote 
17) 
 
Audit/Clinical audit 
 
Quality of life measures can be used to audit service performance from the 
patient perspective. They can be used to audit changes to clinical service delivery 
or effectiveness of educational programmes as well as for comparison of 
outcomes of different service providers. (Quotes 18) 
 
Administration/policy 
 When prioritising patient referrals to a clinic, QoL scores could be used to 
identify patients needing an urgent appointment because of the high impact of 
the disease on their lives. Information from QoL measures may inform policy 
makers and inform decisions about which aspects of a service need to be 
developed. Quality of life scores can be used to identify patients needing 
expensive therapy and justify its use. The use of structured QoL measures may 
allow allied health personnel to act more independently of physicians. Quality of 
life measures may be used by patients as advocacy tools, quantifying and 
formalising their complaints. (Quotes 19) 
 
 
One participant commented that patients are pleased that these issues are being 
tackled and that no patients had ever given any negative feedback on the use of QoL questionnaires.  Another participant quoted that ǲonly when you can 
measure something can you talk about itǳ, and that the focus in medicine 
towards management of chronic disease emphasises the important of measuring 
QoL in clinical practice. 
 
Discussion 
 
Previous authors have addressed the potential benefits of routinely using QoL 
measures in a dermatology clinic8,9,7.  Abeni et al8 suggested that the (routine) 
measurement of QoL would help to identify patients experiencing major negative 
impact of their skin disease and may therefore need treatments that would not be the usual ǲfirst-lineǳ treatments based on clinical severity alone, or other 
special support. Salek et al9 suggested that improving QoL is becoming an 
explicit goal of healthcare in dermatology consultations. Van Cranenburgh et al7 
identified why HRQoL assessment is relevant for dermatologic practice and 
which patients would benefit most from routine HRQoL assessment.  Aawar et 
al10 suggested that using a patientǯs QoL information can lead to optimized 
treatment decision-making, and be used to prioritize problems, facilitate 
communication, screen for potential risks, identify preferences and monitor 
response to treatment.  Other potential benefits are in the training of new staff, 
in clinical audit and for clinical governance.  
 
Cella et al12 summarized the possible benefits of using patient reported 
outcomes in clinical care as: assisting clinical providers in managing their patientsǯ care16: enhancing the efficiency of clinical practice17,18; improving 
patient-provider communication17,19; identifying patient needs in a timely 
manner17,20; and facilitating patient-centered care17.  All of these various points 
were mentioned independently by our study participants. 
 
Although many dermatologists think they have good insight into the impact of 
disease on their patients, the concordance between clinician-reported 
measurements of disease burden and PRO measures appears to be poor21,22,23.  
Little information about QoL is normally elicited during routine dermatology 
outpatient consultations21, though dermatologistsǯ clinical decisions in 
outpatients concerning psoriasis management are related to the degree of 
impact of psoriasis on the patientǯs QoL24.  Salek et al25 demonstrated that the 
routine use of QoL measures identified patients experiencing high impact on 
QoL.  In 29% of consultations where a QoL measure was completed, the clinician used the QoL information and in 58% of these ǳuseǳ consultations the QoL 
information influenced treatment decision taking, mainly in patients who were 
more severely affected than recognised by the clinician.  Tabolli et al26 found that 
using QoL assessment routinely in a dermatology unit was well accepted by 
patients and clinical staff, however the actual impact on clinical activities was 
limited. Finally, the use of QoL measures may contribute to giving patients ǲperceived controlǳ over their skin condition, thereby improving the doctor-
patient relationship27. 
 
In dermatology and in other specialties, there is some evidence about possible 
advantages for routine use of a QoL measure.  For example, routine use of a QoL 
measure in an oncology practice raised awareness amongst physicians of patient 
functioning and facilitated communication without prolonging the 
consultation13. There were many episodes of the QoL measure identifying issues 
that might not otherwise have been recognised, including depression, erectile 
dysfunction and therapy-induced fatigue. Moreover, a study to compare the use 
of three different QoL measures in a breast/prostate cancer clinic28 unexpectedly 
demonstrated that participants from minority racial groups, with lower 
education and who had less computer usage were more likely to rate the use of a 
QoL measure favorably.  This suggested that using patient reported outcome 
measures in clinical practice may be an effective approach for addressing the 
needs of these groups, a point not raised in our study. Furthermore, the routine 
use of QoL measures may act as an ongoing educational process for the clinician, 
who may gain a greater insight into the reality of living with skin disease.  In 
exceptional cases having the level of QoL impairment documented could provide 
evidence of appropriate clinical decision taking should that ever be challenged. 
 
In urticaria management, routine use of QoL measures may improve and 
standardize medical record keeping and care but also release time for the actual 
physician-patient interaction29.  Evers et al30 emphasized the advantages for 
personalized healthcare approaches. For example, QoL instruments enable the 
identification of patients who would most likely benefit from treatments. Only 
those patients at need for help are offered treatment and patients can be offered 
treatments specifically tailored to their adjustment problems. Insight is also 
gained into treatment priorities and patient motivation. In addition, screening of 
risk and resilience factors may provide clues on where and how to intervene in a 
specific patient. 
 
Our study was not designed to document negative aspects of the use of QoL 
measures but it is important to recognise that there are potential issues.  One 
barrier has been the perception of increased work burden for the patient and 
physician13,31, but there may be no overall increased work burden for providers 
if QoL measures are used13.  It is important that QoL questionnaires are not just 
completed by but are discussed with patients.  If a patient completes a 
questionnaire but nothing is apparently done with it, this reduces motivation to 
complete another in the future.  However one study participant stated that 
patients are very pleased when QoL measures are used and no patient had ever 
given negative feedback to them about their use. 
 
It is likely that the use of computer-based assessment of QoL will become 
integrated into clinical practice: the use of such a tool designed for children has 
been successfully trialled32: its use was considered to have the potential to 
improve patient-physician communication. However, the implementation of a 
web-based system to collect patient reported outcomes including QoL 
encountered some logistical issues and time constraints33. 
 
One practical aspect of the use of QoL measures in routine clinical practice not 
mentioned by the participants is the importance of clinicians to be able to 
interpret the scores, and also to have a basic understanding of the Minimal 
Clinically Important Difference (MCID) of scores.  Validated descriptor score 
bands and cut-off scores may be helpful to clinicians34,35,36. There is great 
potential for such information and instant interpretation of scores to be given 
automatically to clinicians if QoL measures were to be used online, both for 
direct clinical purposes and for screening30. 
 
Another aspect is the potential in paediatric consultations of enhancing the 
communication between children and their parents or carers.  By comparing the 
results of a QoL measure completed by a child with the assumption of the parent, 
the parent may gain a greater understanding of the childǯs perspective37.  
 
There are few publications that either describe or suggest the use of QoL 
measures in routine clinical practice, or describe the use of QoL information to 
support clinical decision-making in routine practice.  Given that there are many 
anecdotal reports of such use, this is an area that requires further 
documentation, validation and dissemination of good practice. Muller et al38 
state that QoL measurement offers major benefits for the treatment of skin 
diseases and that first experiences of implementing QoL measures into practice 
have been positive.  Although we did not carry out a systematic review regarding 
advantages and disadvantages of integrating QoL measurements in routine 
clinical practice across all medical specialties, it is likely that the advantages and 
disadvantages identified in this Opinion Statement would equally apply in other 
medical specialities. However, as the experience of the contributors was mainly 
in dermatology, caution should be taken in the application of the results to other 
fields of medicine.  
 
In conclusion, the 20 different potential aspects of benefit of routine use of QoL 
measures in routine practice that have been suggested by the study participants 
provide clear encouragement for the wider gaining of experience of their use.  
However, there is virtually no evidence to back up most of these suggestions, 
highlighting a wide array of research questions that need to be prospectively 
addressed. 
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Table 1. The 20 descriptors, given in five categories, of the 108 items mentioned 
by the 13 participants (median number of items mentioned per participant = 8, 
range 4-15). 
 
  Number times items mentioned     Number of clinicians 
       mentioning these items 
 
1. INFORM CLINICAL DECISIONS 
 
Aid treatment decision taking 8   8  
Guideline use   1   1  
Shared decision taking  4   3 
Treatment goals   2   1 
Treatment adjustment at follow-up 3  3 
Discharge decisions   2   2 
 
2. CLINICIAN-PATIENT COMMUNICATION 
 
Clinician-Patient relationship 4   3 
Clinician-Patient enhanced dialogue 11  7 
 
3. AWARENESS OF SKIN DISEASE BURDEN: IMPACT ON CLINICIAN AND ON 
PATIENT 
 
Impact on clinician   20   8 
Impact on patient   6   4  
 
4. INFORMING THE CONSULTATION 
 
Structured clinical assessment 1   1 
Prediction outcomes/prognosis 4   3 
Adherence/Compliance  3   3 
Screening    7   5 
Monitoring    10   9 
Education    5   4 
Referral to other services  4   4 
 
5. CLINICAL SERVICE ADMINISTRATION 
 
Guideline development  1   1 
Audit/Clinical Audit  6   4 
Administration/policy  6   4 
 
 
 
 
  
 
 
 
 
Appendix 1 
Quotes from participants illustrating each concept 
 
 
Guide clinical decisions 
 
Quote 1: Aid treatment decision taking.   
ǲ… QoL measurement may … help dermatologists in making more informed, and 
thus – hopefully - better, decisions about the treatment/management of their 
patient’s diseases.ǳ 
 
Quote 2: Guideline use 
 ǲUse as part of guideline protocols, e.g. NICE or BAD guidelines.ǳ 
 
Quote 3: Shared decision taking 
 ǲBy assessing health-related QOL in clinical practice and discussing the results 
with the patient, patients with chronic skin diseases are directly involved in the 
care process. This in turn contributes to shared-decision making and higher patient 
satisfaction.ǳ 
 
Quote 4: Treatment goals 
ǲ….necessary in determining the treatment - what are the treatment goals?ǳ  
 
Quote 5: Treatment adjustment at follow-up 
ǲ….adjusted my therapy in order to reduce sooner the impact (sometimes, the 
therapy could be different than we had thought before measuring the QoL)ǳ 
 
Quote 6: Discharge decisions 
ǲUse to support clinical decision taking (discharge or follow-up)ǳ 
 
Clinician-patient communication 
 
Quote 7: Clinician-patient relationship ǲIt’s a way of showing we care, that we are interested in the person, as well as the 
skin condition.ǳ 
 
Quote 8: Clinician-patient enhanced dialogue 
ǲInsight in HRQoL problems creates an opportunity to communicate in an empathic 
and responsive way, thereby supporting patients in coping with their problems 
more effectively. …. may be helpful in engaging patients in a discussion on 
treatment preferences to allow mutual- or shared decision making.ǳ   
 
Awareness of skin diseases burden 
 Quote 9: Impact on clinician 
ǲAt a glance we know which domains are most affected (in this way we can focus 
on the issues that are affecting the patient most) .... Great way of doing 
psychodermatology in your everyday practice.ǳ 
 
Quote 10: Impact on patient 
ǲBy filling out a HRQoL questionnaire .... patients may gain more insight into the 
impact of the skin disease on their own physical, psychological and social 
functioning and well-being. …. this insight will increase patients’ self-awareness, for 
instance awareness of specific psychological problems and of specific health care 
needs. Such awareness, and the acknowledgement of needs by the dermatologist, 
may further empower patients to share and discuss their problems with significant 
others, such as a partner, relatives and friends.ǳ 
 
Information aid for prognosis, monitoring, screening, adherence and 
referral 
 
Quote 11: Prediction outcomes/prognosis 
ǲMade a prediction about the future cooperation and patient’s adherence and 
commitment for a long-term treatment.ǳ  
 
Quote 12: Adherence/compliance 
ǲThe doctor’s perception of the patient’s quality of life may influence patient 
satisfaction with care and adherence to treatment.ǳ 
 
Quotes 13: Screening 
ǲUse to identify patients who may need psychological support or referral to nurse 
specialists.ǳ 
ǲFurthermore, patients’ needs for additional care, as a supplement to regular 
dermatological care, can be identified and addressed.ǳ  
 
Quotes 14: Monitoring of disease course 
ǲ…to monitor treatment over time, modify treatment if needed and to determine 
treatment effectiveness.ǳ 
ǲMonitoring the course of a condition, or evaluating the effectiveness of treatment, 
from the point of view of the patient is different than from the point of view of the 
doctor.ǳ 
ǲAn improvement in HRQoL, which is a main treatment goal for many patients, can 
be monitored, and may indicate treatment effectiveness.ǳ 
 
Quote 15: Education 
ǲIndividualization of the educational part of consultation according to patients 
need.ǳ 
 
Quote 16: Referral to other services 
ǲTo define patients who need consultations of specialists other than dermatologists 
(psychologists, psychiatrists etc).ǳ 
 
Clinical service administration 
 
Quote 17: Guideline use/development 
ǲForming of disease-specific recommendations that may include peculiarities of 
different age groups, gender differences and correlations with …. patients’ outcome 
measures.ǳ 
 
Quotes 18: Audit/Clinical audit 
ǲUse to assess changes in way clinical service is provided for patients, (e,g, 
introduction of nurse-led clinics).ǳ 
ǲto track …. the performance of health care delivery organizations: to evaluate a 
clinic´s quality of care over time, to compare the quality of care across clinics.ǳ  
 
Quotes 19: Administration/policy 
ǲUse to identify patients who have been referred who need to be seen urgently.ǳ 
ǲBy providing a self-reported significant outcome measure it allows allied health 
personnel to act more independently of physicians, e.g. in nurse-led clinics.ǳ 
 
 
 
